Search results
Cerevel Sued Over Stock Sale to Bain Ahead of AbbVie Deal News
Bloomberg Law· 5 days agoBain Capital LP affiliates may have arranged to buy stock on the cheap when they knew Cerevel Therapeutics Holdings Inc. was set to be acquired by AbbVie Inc. for $8.7 billion, a newly filed lawsuit says.
With 72% ownership, AbbVie Inc. (NYSE:ABBV) boasts of strong institutional backing
Simply Wall St. via Yahoo Finance Canada· 6 days agoKey Insights Significantly high institutional ownership implies AbbVie's stock price is sensitive to...
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
Zacks via Yahoo Finance Canada· 7 days agoAbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult...
Company News for Jul 3, 2024
Zacks via Yahoo Finance Canada· 5 days agoShares of Apple Inc. AAPL rose 1.6% on the continued mega-cap growth stock rally. iQIYI, Inc.’s IQ shares rose 1.4% on consumer discretionaries scoring a...
MedinCell And Two More Euronext Paris Growth Stocks With High Insider Ownership
Simply Wall St. via Yahoo Finance Canada· 5 days agoAs the French market navigates through a period of political uncertainty with upcoming elections,...
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
Zacks via Yahoo Finance Canada· 3 days agoEli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi...
Top Insider-Owned Growth Companies On Euronext Paris July 2024
Simply Wall St. via Yahoo Finance Canada· 6 days agoAmid a backdrop of heightened political uncertainty and fluctuating market indices, France's...
2 Boston Partners Mutual Funds for Maximum Returns
Zacks via Yahoo Finance Canada· 3 days agoRamallo has been the lead manager of BPAVX since Dec 30, 2007. Most of the fund’s holdings were in companies like Johnson & Johnson (2.2%), JPMorgan...
Continuous bioprocessing set to revolutionize cGMP manufacturing of biologics
BioPharma-Reporter· 3 days agoConsequently commercial demands of many of these next generation therapeutics are lower, ranging...